MedWatch·Industry news·OTC / consumer·3mo agoSamsung gets FDA approval – takes leap into US OTC marketSamsung has received FDA approval to enter the US over-the-counter hearing aid market, a move analysts at Carnegie describe as a potential driver pushing consumers toward traditional hearing aids.+Save
MedWatch·Industry news·Business & finance·3mo agoDemant buys Amplifon’s UK chain: “We decided to make this a major project”Demant acquired Amplifon's UK retail clinic chain, strengthening its direct-to-consumer hearing care presence in the UK market despite the deal appearing as a minor line item in financial statements.+Save
MedWatch·Industry news·Business & finance·3mo agoDemant CEO steps up efforts despite tough competition ahead: “We’re not done yet”Demant CEO Søren Nielsen expresses confidence in the company's revised growth forecast amid intensifying competition from new product launches by rival hearing-aid manufacturers.+Save
MedWatch·Industry news·Business & finance·3mo agoWSA chief maintains approach despite loss of key client in the US: “It’s mainly a choice on the client’s part”WSA CEO Jan Mäkelä says new product launches and US market breadth will offset an expected EUR 60–80m revenue shortfall following the loss of a key US client.+Save
MedWatch·Industry news·Business & finance·3mo agoAnalyst expects tense competition following Demant's improved outlookAn analyst expects heightened competition following Demant's improved outlook and the launch of Oticon Reveal, citing new product launches from rivals GN and Sonova.+Save
MedWatch·Industry news·Business & finance·3mo agoWSA will not renew major contract with US managed care clientWSA has lost a major contract with a US managed care organization, with the loss expected to negatively impact the company's revenue in the 2026/27 financial year.+Save
MedWatch·Financial report·Business & finance·3mo agoDemant CEO on upward revision: “There is strong momentum in the business”Demant CEO Søren Nielsen comments on an upward financial revision, citing strong organic growth across all three of the company's business areas.+Save
MedWatch·Financial report·Business & finance·3mo agoDemant upgrades outlook and launches new product initiativeDemant raised its organic growth forecast to 6–7% for the year, up from a prior 3–6% projection, and announced a new product initiative.+Save
MedWatch·Industry news·Hearing aids·3mo agoDivested GN division launches new AI-based hearing aid platformGN Hearing's newly divested division launched ReSound Sensia, a hearing aid platform using AI to prioritize intended sounds for the listener.+Save
MedWatch·Financial report·Business & finance·3mo agoDemant upgrade widely expected up to Q2 reportAnalysts widely expect an earnings upgrade from Demant ahead of its Q2 report, citing the recent launch of the Oticon Zeal hearing aid as a positive driver for the company's performance.+Save
MedWatch·Financial report·Business & finance·3mo agoAmplifon's value goes up after earnings reportAmplifon's market valuation rose following an earnings report showing 4.7% organic growth in Q2.+Save
MedWatch·Financial report·Business & finance·3mo agoPositive outlook at Demant prompts Nordea to raise its price targetNordea raised its price target for Demant following a positive company outlook, with several banks suggesting Demant's own annual expectations may be overly conservative.+Save
MedWatch·Financial report·Hearing aids·3mo agoDemant launch could boost the market for cosmetic hearing aidsUBS analysts note that Demant's cosmetic hearing aid launch may boost that market segment, while Sonova poses increasing competition in the largest hearing aid category.+Save
MedWatch·Industry news·Business & finance·4mo agoDemant grew market share among US veterans in JuneDemant grew its market share among US veterans in June, while GN Hearing—soon to be acquired by Italian company Amplifon—also increased its market share.+Save
MedWatch·Industry news·Business & finance·4mo agoUS hearing aid company Eargo closesUS hearing aid company Eargo has shut down its operations after its parent company began winding down activities in the United States.+Save
MedWatch·Industry news·Business & finance·4mo agoGN Hearing's Italian buyer elated after upgraded recommendationAmplifon announced the acquisition of GN Hearing's hearing aid business for DKK 17 billion in early March, with the Italian buyer receiving an upgraded analyst recommendation following the deal.+Save
MedWatch·Financial report·Business & finance·4mo agoDistrust of GN' management as Demant surges aheadFollowing the sale of GN Hearing, investors are expressing distrust in GN's management and questioning the company's next strategic direction as rival Demant gains market momentum.+Save
MedWatch·Financial report·Business & finance·4mo agoBank of America looks favorably upon Demant's launch of Oticon ZealBank of America analysts issued a favorable assessment of Demant, citing the launch of the Oticon Zeal hearing aid as the key factor driving their positive outlook.+Save
MedWatch·Industry news·Regulatory & legal·4mo agoDemant suspends protection programs after Danish FSA orderDemant has suspended protection programs following an order from the Danish Financial Supervisory Authority directed at its hearing aid brand Oticon and French hearing care chain Audika.+Save
MedWatch·Industry news·Business & finance·4mo agoDemant has made IT security a top priority after cyberattack in 2019Demant has made IT security a cultural priority following a 2019 cyberattack, with its IT director noting that employees now receive ongoing training to prevent future incidents.+Save
MedWatch·Industry news·Business & finance·4mo agoMedia: Investors criticize GN board following hearing aid business saleShareholders are criticizing GN's board of directors for excluding major hearing aid manufacturers Demant and Sonova from the bidding process for GN's hearing aid business sale, according to Berlingske.+Save
MedWatch·Industry news·Business & finance·4mo agoDemant on track for best quarter since the turn of the millenniumDemant is on track for its best quarter since 2000, with momentum attributed primarily to the strong market launch of the Oticon Zeal hearing aid.+Save
MedWatch·Industry news·Business & finance·5mo agoAmplifon secures billion-euro loan for GN Hearing acquisitionAmplifon has secured a €1.3 billion senior loan from multiple international banks to finance its planned acquisition of GN Hearing.+Save
MedWatch·Financial report·Business & finance·5mo agoMorgan Stanley upgrades Demant and Sonova on positive market prospectsMorgan Stanley upgraded Demant and Sonova stocks, citing positive market prospects and an anticipated turning point for the hearing aid sector following two years of slowdown.+Save
MedWatch·Industry news·Business & finance·5mo agoWSA chairman highlights IPO in search for new CFOWS Audiology chairman Lars Rasmussen acknowledged CFO Marianne Wiinholt's departure as a loss and stated that her successor must be capable of guiding the company through a potential IPO.+Save
MedWatch·Industry news·Business & finance·5mo agoWSA CEO on CFO departure: "She's been a trusted partner"WS Audiology CFO Marianne Wiinholt, who has held the finance chief role for four years, announced her planned departure from the hearing aid company.+Save
MedWatch·Industry news·Business & finance·5mo agoChief of finance resigns from WS AudiologyWS Audiology's Chief Financial Officer Marianne Wiinholt has resigned at her own request to pursue board and advisory roles.+Save
MedWatch·Industry news·Hearing aids·5mo agoDemant product stands out in new market analysisA Barclays market analysis found that approximately 80% of respondents rated the Oticon Zeal hearing aid, made by Demant, as superior to competing products.+Save
MedWatch·Financial report·Business & finance·5mo agoBarclays warns that hearing aid market's comeback could be short-livedBarclays warns that the hearing aid market's Q1 recovery may be short-lived, as more consumers delay purchases or trade down to cheaper models despite a stronger US market.+Save